The Rise of Remicade Biosimilars
Regulatory Approvals Open Floodgates for Biosimilar Competition
The US Food and Drug Administration's (FDA) approval of the first Infliximab biosimilar, Inflectra, in 2016 marked a pivotal moment for the biosimilars industry. With Infliximab being one of the highest grossing biologic drugs of all time, its patent expiration left the door open for biosimilar competition that could drastically lower treatment costs for patients with immune-mediated inflammatory diseases. In the years since, multiple other Infliximab biosimilars have gained FDA approval, ushering in a new era of lower-cost biologic options.
Get More Insights On- Remicade Biosimilars(https://hallbook.com.br/bl...
)
Regulatory Approvals Open Floodgates for Biosimilar Competition
The US Food and Drug Administration's (FDA) approval of the first Infliximab biosimilar, Inflectra, in 2016 marked a pivotal moment for the biosimilars industry. With Infliximab being one of the highest grossing biologic drugs of all time, its patent expiration left the door open for biosimilar competition that could drastically lower treatment costs for patients with immune-mediated inflammatory diseases. In the years since, multiple other Infliximab biosimilars have gained FDA approval, ushering in a new era of lower-cost biologic options.
Get More Insights On- Remicade Biosimilars(https://hallbook.com.br/bl...
)
07:42 AM - Dec 15, 2024 (UTC)
